Curium to Acquire Lantheus in Up to $8 Billion Radiopharma Deal
Curium will buy Lantheus for $102.50/share cash plus up to $12 CVRs, valuing the radiopharma deal at up to $8B. Closing expected in H1 2027.
/ 5 items
#LNTH↓
Curium in Advanced Talks to Acquire Lantheus for About $7 Billion
Curium is in advanced talks to buy Lantheus for ~$7B ($102/share + $12.50 CVRs). Announcement possible soon; no final deal confirmed yet.
Lantheus Gets FDA CRL for LNTH-2501; No Safety or Efficacy Concerns Raised
The delay is due to manufacturing issues at a third-party facility, with no safety or clinical data concerns.
Curium Makes $7 Billion Takeover Offer for Lantheus Holdings
Lantheus is in talks to be bought by Curium for about $7B. No deal yet. Stock rose. Deal would be big in nuclear medicine.
New Partnership Brings Leading Prostate Cancer Detection Tool to Japan
Lantheus licenses PYLARIFY, a leading PSMA PET imaging agent for prostate cancer, exclusively to GE HealthCare for development, manufacturing, and sales in Japan, a key international market.